Physician profile

Sidharth C Panchamia

Interventional Pain Medicine · Riverview, FL

NPI 1275735276

$21,598.61

in general payments reported to CMS, 2019-2025

43 companies · $783 in 2025

The $783 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,348.31
Travel and Lodging$1,044.17

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ziehm-Orthoscan, INC. $10,631.91 2020-2022
Boston Scientific Corporation $4,543.69 2020-2025 General - Pain Management, Intracept, Wavewriter Alpha Prime 16
Vertos Medical, INC. $1,225.79 2019-2023 Mild Device Kit
Si-Bone, INC. $1,222.69 2023-2025
Spinal Simplicity, LLC $834.22 2021-2024 Ha Minuteman G3-R
Abbott Laboratories $813.55 2019-2024 Eterna, Proclaim
Spr Therapeutics, INC $305.01 2022-2025 Sprint Pns System
Nevro Corp. $192.47 2019-2024 Senza
Collegium Pharmaceutical, INC. $160.22 2019-2021
Almatica Pharma LLC $139.19 2021-2023 Gralise
Scilex Pharmaceuticals INC. $136.78 2019-2021
Spinefrontier, INC. $128.87 2024 Inspan, Sijfuse, Nanofuse
Amgen INC. $109.26 2019-2022
Curonix LLC $97.95 2024 Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A
Stimwave Technologies Incorporated $95.62 2021-2022
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Kowa Pharmaceuticals America, INC. $94.39 2022-2023 Seglentis
Teva Pharmaceuticals USA, INC. $91.19 2020-2021
Abbvie INC. $75.65 2022-2023
Saluda Medical Americas, INC. $66.24 2023-2025 Evoke, Evoke Scs
Horizon Therapeutics Plc $57.06 2019-2020
Zimmer Biomet Holdings, INC. $54.65 2022
Lilly USA, LLC $52.62 2022-2023 Reyvow, Emgality
Medtronic, INC. $47.27 2023-2024 Intellis Adaptivestim
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $41.40 2019-2020
Fidia Pharma USA INC. $38.97 2025 Hymovis, Triluron
Daiichi Sankyo INC. $37.73 2019
Radius Health, INC. $33.13 2021
Biodelivery Sciences International, INC. $32.98 2021
Allergan, INC. $22.70 2020
Biotronik Nro, INC. $21.30 2025 Prospera
Novartis Pharmaceuticals Corporation $20.56 2021
Medtronic USA, INC. $19.12 2019
Electronic Waveform Lab, INC. $17.40 2020
Medline Industries Lp $15.29 2019
Painteq LLC $14.92 2023 Painteq
Pfizer INC. $14.91 2019
Foundation Fusion Solutions, LLC $14.43 2024
Assertio Therapeutics, INC. $13.99 2019
Forte Bio-Pharma LLC $13.77 2024 Prolate, Nalocet
Nalu Medical, INC. $13.63 2022
Grt US Holding, INC. $12.85 2020
Pernix Therapeutics Holdings, INC. $12.09 2019
International Rehabilitative Sciences, INC $11.15 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sidharth C Panchamia

$21,598.61

in general payments reported 2019-2025

Years
2019-2025
Top company
Ziehm-Orthoscan, INC.
Context
The $783 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).

https://glasscript.com/doctor/12136/sidharth-c-panchamia

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.